CCL5 and breast cancer: In addition, capivasertib can also significantly increase the expression of IFNB1, IFIT1, and CCL5, downstream molecules of the cGAS‐STING pathway in endocrine resistant breast cancer (Figure S5C, Supporting Information), suggesting that capivasertib can also improve the activity of cGAS‐STING pathway in endocrine‐resistant breast cancer.